Skip to main navigation Skip to search Skip to main content

The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria

W. H. Boehncke*, R. J. Ludwig, T. M. Zollner, F. Ochsendorf, R. Kaufmann, B. F. Gibbs

*Corresponding author for this work
Original languageEnglish
JournalBritish Journal of Dermatology
Volume148
Issue number3
Pages (from-to)604-606
Number of pages3
ISSN0007-0963
DOIs
Publication statusPublished - 01.03.2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this